Alvotech (ALVO) Stock Price

Alvotech Price

NASDAQ·CLOSED
4.93
​
Market closed

Revenue has compounded at 62.4% per year over the past 6 years to 586.32 M USD. Alvotech's net margin stands at 4.8%, up from -276.0% several years earlier. Analysts set a median price target of 10.00 USD, implying 102.8% above the current price. Of 13 analysts, 11 rate the stock a buy — an overall Buy consensus.

Alvotech stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alvotech business model & stock analysis

Alvotech operates as a global biopharmaceutical company, which engages in developing and manufacturing biosimilar medicines. The firm is focused on the development and manufacture of biosimilar medicines for patients globally. The company is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). The company has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.

Frequently asked questions about Alvotech

Analysts currently set an average price target of 8.60 USD for the Alvotech stock (median: 10.00 USD), implying +74.1 % versus the latest price. The consensus is based on 13 analyst ratings.

13 analysts currently rate the Alvotech stock: 11 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Alvotech to generate revenue of 587.59 M USD and earnings per share of -0.01 USD.

Converted at the current exchange rate, the Alvotech share trades at 4.42 EUR (4.93 USD).

The Alvotech share (ALVO) is listed on 3 stock exchanges, including: NASDAQ (ALVO), Frankfurt (Z45.F), München (Z45.MU).

The expected revenue of Alvotech is 587.59 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Alvotech is -3.74 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Alvotech is currently -367.91. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Alvotech stock.

The price-to-sales ratio (P/S) of Alvotech is currently 2.34. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Alvotech stock.

The Eulerpool Quality Score for Alvotech is 3/10.

The ISIN of Alvotech is LU2458332611. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Alvotech is A3DK8U. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Alvotech is ALVO. The ticker symbol is used to trade Alvotech shares on the stock exchange.

Fair ValueTerminal
4.93 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
390,880.67 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website
Country
Luxembourg
Currency
USD
Initial public offering
Nov 9, 2020
ISIN
LU2458332611
Cusip
L01800108
Market capitalization
1.38 B USDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-367.91
P/Ee 2027
21.38
P/Ee 2028
10.71
P/Ee 2029
5.71
P/Ee 2030
3.89
P/S
P/Se
2.34
EV/EBIT
31.72
P/B Ratio
—
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
2.40 %
Last updated Oct 29, 2026, 8:15 PM

Alvotech Peer Group

Alvotech Ticker

FRANKFURT · Z45.FMUNICH · Z45.MUNASDAQ · ALVO

Alvotech FIGI

ALVO:US · BBG014MBMZY2ALVO:UA · BBG017ZKJJV4ALVO:UC · BBG017ZKJJX2ALVO:UN · BBG017ZKJJZ0ALVO:UP · BBG017ZKJK05ALVO:UQ · BBG017ZKJK14ALVO:UB · BBG017ZKJK23ALVO:UM · BBG017ZKJK50ALVO:UX · BBG017ZKJK69ALVO:UD · BBG017ZKJKD1ALVO:UF · BBG017ZKJKH7ALVO:VY · BBG017ZKJKJ5

All fundamentals and in-depth analysis of Alvotech

Our stock analysis for Alvotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Alvotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.